Back to News
Market Impact: 0.2
Lucid Capital Markets Initiates Coverage of Faeth Therapeutics with Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Lucid Capital Markets initiated coverage of Faeth Therapeutics (NASDAQCM:FTH) with a Buy rating on September 14, 2026. FTH closed at $39.02 on the rating date, following a prior close of $37, signaling a modestly positive analyst catalyst for the biotech stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
FTH0.55
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Hong Kong unveils first five-year plan to add jobs, homes, align closer to mainland China
- Beta Bionics prices $150M public offering at $17.25/share
- BofA Sees Chance of $150 Oil on Critical Infrastructure Risk
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- Angela Mwanza Sees 25-Basis-Point Fed Cut